The significance of Her2 on androgen receptor protein stability in the transition of androgen requirement in prostate cancer cells

American Journal of Physiology - Endocrinology and Metabolism

Volumn 300, Issue 5, 2011, Pages

  Hsu, Fu Ning ^a   Yang, Min Shiou ^a   Lin, Eugene ^a,c   Tseng, Chun Fu ^a   Lin, Ho ^a,b  

^a NATIONAL CHUNG HSING UNIVERSITY   (Taiwan)

^b CHINA MEDICAL UNIVERSITY   (Taiwan)

^c CHANG BING SHOW CHWAN MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Androgen independent; LNCaPdcc

Indexed keywords

ANDROGEN RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 4; METRIBOLONE; NEU DIFFERENTIATION FACTOR; NLP 005; PHOSPHOSERINE; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG;

ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER CELL; CANCER GROWTH; CELL CYCLE; CELL PROLIFERATION; CELL STRAIN LNCAP; CONCENTRATION RESPONSE; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN STABILITY;

ANDROGENS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BENZOTHIAZOLES; BLOTTING, WESTERN; CELL CYCLE; CELL LINE; CELL SURVIVAL; CELLS, CULTURED; HUMANS; MALE; METRIBOLONE; PROSTATIC NEOPLASMS; PROTEIN-TYROSINE KINASES; RECEPTOR, ERBB-2; RECEPTORS, ANDROGEN; TRYPAN BLUE; TYRPHOSTINS;

EID: 79955563441     PISSN: 01931849     EISSN: 15221555     Source Type: Journal    
DOI: 10.1152/ajpendo.00610.2010     Document Type: Article

References (35)

1. Berger R, Lin DI, Nieto M, Sicinska E, Garraway LA, Adams H, Signoretti S, Hahn WC, Loda M. Androgen-dependent regulation of Her-2/neu in prostate cancer cells. Cancer Res 66: 5723-5728, 2006.
2. Burd CJ, Petre CE, Moghadam H, Wilson EM, Knudsen KE. Cyclin D1 binding to the androgen receptor (AR) NH2-terminal domain inhibits activation function 2 association and reveals dual roles for AR corepression. Mol Endocrinol 19: 607-620, 2005. 2a.Chen MC, Lin H, Hsu FN, Huang PH, Lee GS, Wang PS. Involvement of cAMP in nerve growth factor-triggered p35/Cdk5 activation and differentiation in PC12 cells. Am J Physiol Cell Physiol 299: C516-C527, 2010.
3. Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, Rosenfeld MG, Sawyers CL. Molecular determinants of resistance to antiandrogen therapy. Nat Med 10: 33-39, 2004.
4. Chen S, Xu Y, Yuan X, Bubley GJ, Balk SP. Androgen receptor phosphorylation and stabilization in prostate cancer by cyclin-dependent kinase 1. Proc Natl Acad Sci USA 103: 15969-15974, 2006.
5. Culig Z, Bartsch G. Androgen axis in prostate cancer. J Cell Biochem 99: 373-381, 2006.
6. Culig Z, Hobisch A, Cronauer MV, Radmayr C, Trapman J, Hittmair A, Bartsch G, Klocker H. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res 54: 5474-5478, 1994.
7. Culig Z, Hoffmann J, Erdel M, Eder IE, Hobisch A, Hittmair A, Bartsch G, Utermann G, Schneider MR, Parczyk K, Klocker H. Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system. Br J Cancer 81: 242-251, 1999.
8. Gelmann EP. Molecular biology of the androgen receptor. J Clin Oncol 20: 3001-3015, 2002.
9. Gioeli D, Ficarro SB, Kwiek JJ, Aaronson D, Hancock M, Catling AD, White FM, Christian RE, Settlage RE, Shabanowitz J, Hunt DF, Weber MJ. Androgen receptor phosphorylation. Regulation and identification of the phosphorylation sites. J Biol Chem 277: 29304-29314, 2002.
10. Gregory CW, He B, Johnson RT, Ford OH, Mohler JL, French FS, Wilson EM. A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. Cancer Res 61: 4315-4319, 2001.
11. Grossmann ME, Huang H, Tindall DJ. Androgen receptor signaling in androgen-refractory prostate cancer. J Natl Cancer Inst 93: 1687-1697, 2001.
12. Heinlein CA, Chang C. Androgen receptor in prostate cancer. Endocr Rev 25: 276-308, 2004.
13. Horoszewicz JS, Leong SS, Kawinski E, Karr JP, Rosenthal H, Chu TM, Mirand EA, Murphy GP. LNCaP model of human prostatic carcinoma. Cancer Res 43: 1809-1818, 1983.
14. Isaacs JT, Isaacs WB. Androgen receptor outwits prostate cancer drugs. Nat Med 10: 26-27, 2004.
15. Kokontis J, Takakura K, Hay N, Liao S. Increased androgen receptor activity and altered c-myc expression in prostate cancer cells after longterm androgen deprivation. Cancer Res 54: 1566-1573, 1994.
16. Kokontis JM, Hay N, Liao S. Progression of LNCaP prostate tumor cells during androgen deprivation: hormone-independent growth, repression of proliferation by androgen, and role for p27Kip1 in androgen-induced cell cycle arrest. Mol Endocrinol 12: 941-953, 1998. 16a.Kuo HS, Hsu FN, Chiang MC, You SC, Chen MC, Lo MJ, Lin H. The role of Cdk5 in retinoic acid-induced apoptosis of cervical cancer cell line. Chin J Physiol 52: 23-30, 2009.
17. Lin H. The versatile roles of cyclin-dependent kinase 5 in human diseases. Adaptive Medicine 1 22-25, 2009.
18. Lin H, Chen MC, Chiu CY, Song YM, Lin SY. Cdk5 regulates STAT3 activation and cell proliferation in medullary thyroid carcinoma cells. J Biol Chem 282: 2776-2784, 2007.
19. Lin H, Chen MC, Ku CT. Cyclin-dependent kinase 5 regulates steroidogenic acute regulatory protein and androgen production in mouse Leydig cells. Endocrinology 150: 396-403, 2009.
20. Lin H, Juang JL, Wang PS. Involvement of Cdk5/p25 in digoxintriggered prostate cancer cell apoptosis. J Biol Chem 279: 29302-29307, 2004.
21. Lin H, Lin TY, Juang JL. Abl deregulates Cdk5 kinase activity and subcellular localization in Drosophila neurodegeneration. Cell Death Differ 14: 607-615, 2007.
22. Lipford JR, Deshaies RJ. Diverse roles for ubiquitin-dependent proteolysis in transcriptional activation. Nat Cell Biol 5: 845-850, 2003.
23. Liu S, Yuan Y, Okumura Y, Shinkai N, Yamauchi H. Camptothecin disrupts androgen receptor signaling and suppresses prostate cancer cell growth. Biochem Biophys Res Commun 394: 297-302, 2010.
24. Marcelli M, Ittmann M, Mariani S, Sutherland R, Nigam R, Murthy L, Zhao Y, DiConcini D, Puxeddu E, Esen A, Eastham J, Weigel NL, Lamb DJ. Androgen receptor mutations in prostate cancer. Cancer Res 60: 944-949, 2000.
25. Mellinghoff IK, Vivanco I, Kwon A, Tran C, Wongvipat J, Sawyers CL. HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability. Cancer Cell 6: 517-527, 2004.
26. Nawaz Z, Lonard DM, Smith CL, Lev-Lehman E, Tsai SY, Tsai MJ, O'Malley BW. The Angelman syndrome-associated protein, E6-AP, is a coactivator for the nuclear hormone receptor superfamily. Mol Cell Biol 19: 1182-1189, 1999.
27. Oxley JD, Winkler MH, Gillatt DA, Peat DS. Her-2/neu oncogene amplification in clinically localised prostate cancer. J Clin Pathol 55: 118-120, 2002.
28. Rhim JS, Kung HF. Human prostate carcinogenesis. Crit Rev Oncog 8: 305-328, 1997.
29. Scher HI, Sarkis A, Reuter V, Cohen D, Netto G, Petrylak D, Lianes P, Fuks Z, Mendelsohn J, Cordon-Cardo C. Changing pattern of expression of the epidermal growth factor receptor and transforming growth factor alpha in the progression of prostatic neoplasms. Clin Cancer Res 1: 545-550, 1995.
30. Sheflin L, Keegan B, Zhang W, Spaulding SW. Inhibiting proteasomes in human HepG2 and LNCaP cells increases endogenous androgen receptor levels. Biochem Biophys Res Commun 276: 144-150, 2000.
31. Shi XB, Ma AH, Xia L, Kung HJ, de Vere White RW. Functional analysis of 44 mutant androgen receptors from human prostate cancer. Cancer Res 62: 1496-1502, 2002.
32. Shi Y, Brands FH, Chatterjee S, Feng AC, Groshen S, Schewe J, Lieskovsky G, Cote RJ. Her-2/neu expression in prostate cancer: high level of expression associated with exposure to hormone therapy and androgen independent disease. J Urol 166: 1514-1519, 2001.
33. Shigemura K, Isotani S, Wang R, Fujisawa M, Gotoh A, Marshall FF, Zhau HE, Chung LW. Soluble factors derived from stroma activated androgen receptor phosphorylation in human prostate LNCaP cells: roles of ERK/MAP kinase. Prostate 69: 949-955, 2009.
34. Tan M, Jing T, Lan KH, Neal CL, Li P, Lee S, Fang D, Nagata Y, Liu J, Arlinghaus R, Hung MC, Yu D. Phosphorylation on tyrosine-15 of p34(Cdc2) by ErbB2 inhibits p34(Cdc2) activation and is involved in resistance to taxol-induced apoptosis. Mol Cell 9: 993-1004, 2002.
35. Veldscholte J, Ris-Stalpers C, Kuiper GG, Jenster G, Berrevoets C, Claassen E, van Rooij HC, Trapman J, Brinkmann AO, Mulder E. A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to antiandrogens. Biochem Biophys Res Commun 173: 534-540, 1990.